HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, 20892, MD, United States.
Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan.
Sci Rep. 2020 Jun 30;10(1):10664. doi: 10.1038/s41598-020-65993-z.
HIV-1 protease inhibitors (PIs), such as darunavir (DRV), are the key component of antiretroviral therapy. However, HIV-1 often acquires resistance to PIs. Here, seven novel PIs were synthesized, by introducing single atom changes such as an exchange of a sulfur to an oxygen, scission of a single bond in P2'-cyclopropylaminobenzothiazole (or -oxazole), and/or P1-benzene ring with fluorine scan of mono- or bis-fluorine atoms around DRV's scaffold. X-ray structural analyses of the PIs complexed with wild-type Protease (PR) and highly-multi-PI-resistance-associated PR revealed that the PIs better adapt to structural plasticity in PR with resistance-associated amino acid substitutions by formation of optimal sulfur bond and adaptation of cyclopropyl ring in the S2'-subsite. Furthermore, these PIs displayed increased cell permeability and extreme anti-HIV-1 potency compared to DRV. Our work provides the basis for developing novel PIs with high potency against PI-resistant HIV-1 variants with a high genetic barrier.
HIV-1 蛋白酶抑制剂(PIs),如达芦那韦(DRV),是抗逆转录病毒疗法的关键组成部分。然而,HIV-1 常常会对 PIs 产生耐药性。在这里,我们通过引入单原子变化(如将硫替换为氧、在 P2'-环丙基氨基苯并噻唑(或恶唑)中切断单键,以及/或在 DRV 支架周围进行单氟或双氟原子的氟扫描)合成了七种新型 PIs。对与野生型蛋白酶(PR)和高度多 PI 耐药相关 PR 复合的 PIs 的 X 射线结构分析表明,这些 PIs 通过形成最佳的硫键和适应 S2'-亚位点中的环丙基环,更好地适应了具有耐药相关氨基酸取代的 PR 的结构可塑性。此外,与 DRV 相比,这些 PIs 显示出增加的细胞通透性和极强的抗 HIV-1 效力。我们的工作为开发针对具有高遗传屏障的耐药性 HIV-1 变异体的高活性新型 PIs 提供了基础。